KRAS and benign neoplasm: Performance of NGS-based assay for the detection of cfDNA KRAS mutations, CA19-9 plasma level and combined assays (40 PDAC, 20 healthy controls, 9 chronic pancreatitis subjects, and 25 benign neoplasm subjects)